Zebrafish as a model to investigate a biallelic gain-of-function variant in MSGN1, associated with a novel skeletal dysplasia syndrome

Asuman Koparir, Caroline Lekszas, Kemal Keseroglu, Thalia Rose, Lena Rappl, Aboulfazl Rad, Reza Maroofian, Nakul Narendran, Atefeh Hasanzadeh, Ehsan Ghayoor Karimiani, Felix Boschann, Uwe Kornak, Eva Klopocki, Ertuğrul M. Özbudak, Barbara Vona, Thomas Haaf, Daniel Liedtke*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Objectives: Rare genetic disorders causing specific congenital developmental abnormalities often manifest in single families. Investigation of disease-causing molecular features are most times lacking, although these investigations may open novel therapeutic options for patients. In this study, we aimed to identify the genetic cause in an Iranian patient with severe skeletal dysplasia and to model its molecular function in zebrafish embryos. Results: The proband displays short stature and multiple skeletal abnormalities, including mesomelic dysplasia of the arms with complete humero-radio-ulna synostosis, arched clavicles, pelvic dysplasia, short and thin fibulae, proportionally short vertebrae, hyperlordosis and mild kyphosis. Exome sequencing of the patient revealed a novel homozygous c.374G > T, p.(Arg125Leu) missense variant in MSGN1 (NM_001105569). MSGN1, a basic-Helix–Loop–Helix transcription factor, plays a crucial role in formation of presomitic mesoderm progenitor cells/mesodermal stem cells during early developmental processes in vertebrates. Initial in vitro experiments show protein stability and correct intracellular localization of the novel variant in the nucleus and imply retained transcription factor function. To test the pathogenicity of the detected variant, we overexpressed wild-type and mutant msgn1 mRNA in zebrafish embryos and analyzed tbxta (T/brachyury/ntl). Overexpression of wild-type or mutant msgn1 mRNA significantly reduces tbxta expression in the tailbud compared to control embryos. Mutant msgn1 mRNA injected embryos depict a more severe effect, implying a gain-of-function mechanism. In vivo analysis on embryonic development was performed by clonal msgn1 overexpression in zebrafish embryos further demonstrated altered cell compartments in the presomitic mesoderm, notochord and pectoral fin buds. Detection of ectopic tbx6 and bmp2 expression in these embryos hint to affected downstream signals due to Msgn1 gain-of-function. Conclusion: In contrast to loss-of-function effects described in animal knockdown models, gain-of-function of MSGN1 explains the only mildly affected axial skeleton of the proband and rather normal vertebrae. In this context we observed notochord bending and potentially disruption of pectoral fin buds/upper extremity after overexpression of msgn1 in zebrafish embryos. The latter might result from Msgn1 function on mesenchymal stem cells or on chondrogenesis in these regions. In addition, we detected ectopic tbx6 and bmp2a expression after gain of Msgn1 function in zebrafish, which are interconnected to short stature, congenital scoliosis, limb shortening and prominent skeletal malformations in patients. Our findings highlight a rare, so far undescribed skeletal dysplasia syndrome associated with a gain-of-function mutation in MSGN1 and hint to its molecular downstream effectors.

Original languageEnglish (US)
Article number23
JournalHuman genomics
Volume18
Issue number1
DOIs
StatePublished - Dec 2024

Funding

First of all, we thank the family for their participation and for sharing relevant information. The authors additionally thank PD Dr. Christina Lillesaar and cooperating zebrafish laboratories for sharing the tp1:VenusPEST transgenic line and hinting us to investigating Notch signaling, Frederik Tessmer for cloning of tbx in situ probes, Angela Borst and Alice Schaaf for help with cell culture experiments. The sk-tol2 -msgn1:mCherry-2A-msgn1 plasmid was a kind gift from the Shinji Takada lab (ExCELLS, National Institutes of Natural Sciences, Okazaki, Japan). U.K. and B.V. are members of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability (ERN-ITHACA) [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516]. F.B. is a participant in the Clinician Scientist Program (CS4RARE) funded by the Alliance4Rare and associated with the BIH Charité Clinician Scientist Program. Open Access funding enabled and organized by Projekt DEAL. B.V. is supported by the German Research Foundation (DFG) VO 2138/7-1 grant 469177153. D.L. is supported by the German Research Foundation (DFG) LI 2411/2-2 grant 397519724. First of all, we thank the family for their participation and for sharing relevant information. The authors additionally thank PD Dr. Christina Lillesaar and cooperating zebrafish laboratories for sharing the tp1:VenusPEST transgenic line and hinting us to investigating Notch signaling, Frederik Tessmer for cloning of tbx in situ probes, Angela Borst and Alice Schaaf for help with cell culture experiments. The sk-tol2-msgn1:mCherry-2A-msgn1 plasmid was a kind gift from the Shinji Takada lab (ExCELLS, National Institutes of Natural Sciences, Okazaki, Japan). U.K. and B.V. are members of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability (ERN-ITHACA) [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516]. F.B. is a participant in the Clinician Scientist Program (CS4RARE) funded by the Alliance4Rare and associated with the BIH Charité Clinician Scientist Program.

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Zebrafish as a model to investigate a biallelic gain-of-function variant in MSGN1, associated with a novel skeletal dysplasia syndrome'. Together they form a unique fingerprint.

Cite this